New prostate cancer treatment shows promise and 'could help 40 per cent' View Image

A double-pronged attack on advanced prostate cancer could help treat as many as two in five patients with late-stage disease, scientists have found. Using drugs that are already being used to treat other cancers, or those in development, can slow tumour growth and trigger cancer cell death, experts found.

Experts at The Institute of Cancer Research, London, tested the new combination against cancer cells which had become resistant to hormone therapy, knowing that among this patient group outcomes are poor when they become resistant to treatment. They set out to find a combination of drugs which attack proteins in the body which promote cancer cell survival.

MCL1 is a protein that promotes cancer cell

See Full Page